The Benefits of Transcranial Photobiomodulation in Lewy Body Disease
NCT: NCT07602296 · NOT_YET_RECRUITING
Brief Summary
Lewy body disease (LBD) is the second leading cause of progressive neurodegenerative dementia. Characterised by a complex clinical picture combining cognitive, motor and behavioural symptoms, it is subject to a high rate of misdiagnosis and lacks a fully effective curative or symptomatic treatment. The LEWY-LIGHT project aims to evaluate, for the first time in LBD, an innovative non-pharmacological approach: transcranial photobiomodulation (PBM). This non-invasive and safe technique uses red/infrared light to stimulate brain cell activity and improve higher cognitive functions, building on already promising results obtained in Alzheimer's and Parkinson's diseases.
Frequently Asked Questions
What is The Benefits of Transcranial Photobiomodulation in Lewy Body Disease?
The Benefits of Transcranial Photobiomodulation in Lewy Body Disease is a clinical trial registered under NCT07602296. Current status: NOT_YET_RECRUITING.
What is the status of NCT07602296?
The current status of NCT07602296 (The Benefits of Transcranial Photobiomodulation in Lewy Body Disease) is: NOT_YET_RECRUITING.
When did The Benefits of Transcranial Photobiomodulation in Lewy Body Disease start?
The Benefits of Transcranial Photobiomodulation in Lewy Body Disease started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.